STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront buys €2.9M of stock in August buyback

Lakefront Biotherapeutics NV (LKFT) reports progress on its ordinary share repurchase program announced on June 9, 2026.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics NV (LKFT) reports progress on its ordinary share repurchase program announced on June 9, 2026. Between August 17 and August 21, 2026, the company repurchased 117,471 shares of its own stock through an independent financial intermediary, at an average price of €24.40 per share for a total of €2,866,035.10.

Across multiple European trading venues, the prices paid ranged from a lowest price of €23.66 to a highest price of €25.70. As of market close on August 21, 2026, Lakefront holds 1,033,528 of its own ordinary shares. The company describes itself as a biotechnology business with a clinical-stage immunology and inflammation portfolio and a strong capital position, and notes that further repurchases are subject to the risks outlined in its SEC filings.

Positive

  • None.

Negative

  • None.
Shares repurchased 117,471 shares Repurchased between August 17 and August 21, 2026 under the buyback program
Average price paid €24.40 per share Average repurchase price for 117,471 shares in August 2026 window
Total repurchase amount €2,866,035.10 Aggregate consideration for shares repurchased August 17–21, 2026
Lowest price paid €23.66 per share Lowest transaction price during the August 17–21, 2026 repurchases
Highest price paid €25.70 per share Highest transaction price during the August 17–21, 2026 repurchases
Treasury shares held 1,033,528 shares Own ordinary shares held as of market close on August 21, 2026
Repurchase program announcement date June 9, 2026 Date the share repurchase program framework was announced
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
discretionary mandate financial
"repurchased 117,471 Lakefront shares via a discretionary mandate to an independent"
independent financial intermediary financial
"shares via a discretionary mandate to an independent financial intermediary"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"within the meaning of the Private Securities Litigation Reform Act of 1995"

FAQ

How many shares did Lakefront Biotherapeutics (LKFT) repurchase in August 2026?
Lakefront Biotherapeutics repurchased 117,471 ordinary shares between August 17 and August 21, 2026 under its previously announced share repurchase program, using a discretionary mandate to an independent financial intermediary.

What prices did LKFT pay for its share repurchases in this 6-K period?
During August 17–21, 2026, Lakefront paid an average price of €24.40 per share, with a lowest price of €23.66 and a highest price of €25.70, for a total cash outlay of €2,866,035.10.

How many treasury shares does Lakefront Biotherapeutics (LKFT) now hold?
As of market close on August 21, 2026, Lakefront Biotherapeutics holds 1,033,528 of its own ordinary shares, following the repurchases executed between August 17 and August 21, 2026.

On which markets did LKFT execute the August 2026 share repurchases?
The repurchases were executed on several European trading venues, including XAMS, CEUX, TQEX, and AQEU, under a discretionary mandate to an independent financial intermediary.

What is the purpose of this Lakefront Biotherapeutics (LKFT) Form 6-K?
The Form 6-K reports Lakefront Biotherapeutics’ acquisition of its own shares under its June 9, 2026 repurchase program and incorporates the related press release (Exhibit 99.1) by reference into several of the company’s Form S-8 registration statements.

What risks does LKFT highlight regarding its share repurchase plans?
Lakefront states that its plans to repurchase ordinary shares are forward-looking statements subject to risks and uncertainties described in its SEC filings, including its most recent Form 20-F and subsequent reports.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On August 25, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated August 25, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: August 25, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 17, 2026 and August 21, 2026, it has repurchased 117,471 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchaseMarket/MTFNumber of sharesAverage price paid (€)Total (€)Lowest price paid (€)Highest price paid (€)
17/08/2026XAMS16,15823.97387,350.8923.8424.20
17/08/2026CEUX2,19623.9852,664.0323.9024.18
17/08/2026TQEX61124.0714,706.5923.9424.20
17/08/2026AQEU1,00824.0424,227.6823.9424.04
18/08/2026XAMS23,09423.82550,184.5323.6624.00
18/08/2026CEUX2,13723.7950,833.2523.6623.94
18/08/2026TQEX73723.8717,593.0723.7023.90
18/08/2026AQEU56223.8213,389.1423.7223.86
19/08/2026XAMS16,67724.83414,059.8924.1625.70
19/08/2026CEUX1,95324.6748,186.3724.3625.52
19/08/2026TQEX1,32924.5232,583.2324.3624.66
19/08/2026AQEU22424.595,507.8924.4024.60
20/08/2026XAMS24,14424.92601,772.3024.3625.68
20/08/2026CEUX2,70925.2968,501.1325.1025.70
20/08/2026TQEX96224.8923,940.0424.4425.14
20/08/2026AQEU1,20925.2530,521.6925.1025.42
21/08/2026XAMS14,69424.38358,210.3324.1425.00
21/08/2026CEUX5,34724.31130,010.1724.1824.84
21/08/2026TQEX38124.579,360.8324.2424.90
21/08/2026AQEU1,33924.2232,432.0524.2224.24
Total 117,47124.402,866,035.1023.6625.70

As of market close on 21 August 2026, Lakefront holds 1,033,528 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases